Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
Implied Volatility Surging for Amphastar Pharmaceuticals (AMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amphastar Pharmaceuticals (AMPH) stock based on the movements in the options market lately.
Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals (AMPH) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 20.51% and 6.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
HCA Healthcare (HCA) Beats on Q2 Earnings, Ups 2024 EPS View
by Zacks Equity Research
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.
UnitedHealth Group (UNH) Q2 Earnings Beat on Strong Optum Unit
by Zacks Equity Research
UnitedHealth Group's (UNH) second-quarter earnings continue to be supported by strong Optum and UnitedHealthcare business lines. Rising medical costs partially offset the positives.
Why Amphastar (AMPH) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
by Sundeep Ganoria
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
Implied Volatility Surging for Amphastar (AMPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 35.06% and 0.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals (AMPH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Amphastar (AMPH) Could Beat Earnings Estimates Again
by Zacks Equity Research
Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
New Strong Sell Stocks for April 26th
by Zacks Equity Research
AMPH, BCML and DHC have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2024.
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $41.52, representing a -1% change from its previous close.
Is Amphastar (AMPH) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Amphastar Pharmaceuticals (AMPH) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $44.03, signifying a -1.21% move from its prior day's close.
New Strong Sell Stocks for March 18th
by Zacks Equity Research
ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
Brokers Suggest Investing in Amphastar (AMPH): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Amphastar Pharmaceuticals (AMPH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Amphastar (AMPH) delivered earnings and revenue surprises of 1.15% and 1.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amphastar Pharmaceuticals (AMPH) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Amphastar Pharmaceuticals (AMPH) stood at $51.91, denoting a +1.29% change from the preceding trading day.
Wall Street Bulls Look Optimistic About Amphastar (AMPH): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.
Amphastar Pharmaceuticals (AMPH) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) reachead $55.51 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML